TCDB is operated by the Saier Lab Bioinformatics Group
« See all members of the family


2.A.3.8.1
L-type neutral amino acid transporter, LAT1 (Na+-independent) (prefers amino acids with branched or aromatic side chains: Phe, Ile, Leu, Val, Trp, His; catalyzes obligatory exchange with μM affinities on the outside and mM affinities on the inside [1000x difference]). Both LAT1 and LAT2 (2.A.3.8.6) catalyze uptake of S-nitroso-L-cysteine. These and other LAT family members are specifically inhibited by 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (Li and Whorton, 2005). Mediates tryptophan:kynurenine exchange (Kaper et al., 2007). Also transports thyroid hormones and their derivatives (Kinne et al., 2011; Krause and Hinz 2017; Krause and Hinz 2019).  The chicken orthologue transports thyrold hormones, especially T2, with low affinity (Nele Bourgeois et al. 2016). Lat1 transports 26 biologically active ultrashort peptides (USPs) into cells as is also true of LAT2 and PEPT1 (Khavinson et al. 2023). The sizes and structures of ligand-binding sites of the amino acid transporters LAT1, LAT2, and of the peptide transporter PEPT1 are sufficient for the transport of the 26 biologically active di-, tri-, and tetra-peptides. Comparative analyses of the binding of all possible di- and tri-peptides (8400 compounds) at the binding sites of the LAT and PEPT family transporters was considered (Khavinson et al. 2023). The 26 biologically active USPs systematically showed higher binding scores to LAT1, LAT2, and PEPT1, as compared with di- and tri-peptides. Most of the 26 studied USPs were found to bind to the LAT1, LAT2, and PEPT1 transporters more efficiently than the previously known substrates or inhibitors of these transporters. Peptides ED, DS, DR, EDR, EDG, AEDR, AEDL, KEDP, and KEDG, and peptoids DS7 and KE17 with negatively charged Asp- or Glu- amino acid residues at the N-terminus and neutral or positively charged residues at the C-terminus of the peptide were found to be the most effective ligands of the transporters under investigation. It can be assumed that the antitumor effect of the KE, EW, EDG, and AEDG peptides could be associated with their ability to inhibit the LAT1, LAT2, and PEPT1 amino acid transporters (Khavinson et al. 2023). LAT1 enables T cell activation under inflammatory conditions in mice (Ogbechi et al. 2023).

Accession Number:Q63016
Protein Name:LAT1 aka SLC7A5 aka MPE16 aka TA1
Length:512
Molecular Weight:55903.00
Species:Rattus norvegicus (Rat) [10116]
Number of TMSs:12
Location1 / Topology2 / Orientation3: Cytoplasm1 / Multi-pass membrane protein2
Substrate alpha-amino acid, thyroid hormone

Cross database links:

RefSeq: NP_059049.1   
Entrez Gene ID: 50719   
Pfam: PF00324   
KEGG: rno:50719   

Gene Ontology

GO:0016324 C:apical plasma membrane
GO:0005829 C:cytosol
GO:0016021 C:integral to membrane
GO:0042605 F:peptide antigen binding
GO:0030154 P:cell differentiation
GO:0007399 P:nervous system development
GO:0015804 P:neutral amino acid transport
GO:0055085 P:transmembrane transport

References (6)

[1] “Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98).”  Kanai Y.et.al.   9726963
[2] “TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation.”  Sang J.et.al.   7532544
[3] “Expression of a system L neutral amino acid transporter at the blood-brain barrier.”  Matsuo H.et.al.   11095508
[4] “Transcriptional regulation of the LAT-1/CD98 light chain.”  Padbury J.F.et.al.   15120633
[5] “Expression of LAT1 and LAT2 amino acid transporters in human and rat intestinal epithelial cells.”  Fraga S.et.al.   16027961
[6] “L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier.”  Tomi M.et.al.   15980244

External Searches:

Analyze:

Predict TMSs (Predict number of transmembrane segments)
Window Size: Angle:  
FASTA formatted sequence
1:	MAVAGAKRRA VAAPATTAAE EERQAREKML EARRGDGADP EGEGVTLQRN ITLINGVAII 
61:	VGTIIGSGIF VTPTGVLKEA GSPGLSLVVW AVCGVFSIVG ALCYAELGTT ISKSGGDYAY 
121:	MLEVYGSLPA FLKLWIELLI IRPSSQYIVA LVFATYLLKP VFPTCPVPEE AAKLVACLCV 
181:	LLLTAVNCYS VKAATRVQDA FAAAKLLALA LIILLGFIQM GKDIGQGDAS NLHQKLSFEG 
241:	TNLDVGNIVL ALYSGLFAYG GWNYLNFVTE EMINPYRNLP LAIIISLPIV TLVYVLTNLA 
301:	YFTTLSTNQM LTSEAVAVDF GNYHLGVMSW IIPVFVGLSC FGSVNGSLFT SSRLFFVGSR 
361:	EGHLPSILSM IHPQLLTPVP SLVFTCVMTL MYAFSRDIFS IINFFSFFNW LCVALAIIGM 
421:	MWLRFKKPEL ERPIKVNLAL PVFFILACLF LIAVSFWKTP LECGIGFAII LSGLPVYFFG 
481:	VWWKNKPKWI LQVIFSVTVL CQKLMQVVPQ ET